- Vaccine Name: mRNA-1653
- Target Pathogen: Parainfluenza virus
- Type: mRNA vaccine
- Status: Licensed
- Host Species for Licensed Use: Human
- Antigen: The sources of the encoded antigens were the hMPV A strain, TN/92-4, and the PIV3 strain, PER/FLA4815/2008. (August et al., 2022)
- Immunization Route: Intramuscular injection (i.m.)
- Approved Age for Licensed Use: 18-49 years of age (August et al., 2022)
- Description: The mRNA-1653 vaccine is bivalent, containing 2 distinct nucleoside-modified mRNA sequences encoding the native, membrane-anchored fusion glycoproteins of hMPV and PIV3 encapsulated in a lipid nanoparticle.(August et al., 2022)
|
